Entrada Therapeutics Reports First Quarter 2022 Financial Results
12 mai 2022 07h00 HE
|
Entrada Therapeutics, Inc.
Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy type 1 On track to submit Investigational New Drug application to the U.S. Food and Drug...
Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022
11 mai 2022 09h30 HE
|
Entrada Therapeutics, Inc.
New non-human primate data demonstrate a durability of response through 12 weeks for lead clinical candidate, ENTR-601-44, for the potential treatment of Duchenne muscular dystrophy Second...
Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference
10 mai 2022 07h00 HE
|
Entrada Therapeutics, Inc.
BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
15 mars 2022 07h00 HE
|
Entrada Therapeutics, Inc.
On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022 $291.1 million in cash and cash equivalents as of December 31, 2021 to advance pipeline of...
Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference
23 févr. 2022 08h00 HE
|
Entrada Therapeutics, Inc.
BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel
05 janv. 2022 08h00 HE
|
Entrada Therapeutics, Inc.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes
17 déc. 2021 08h00 HE
|
Entrada Therapeutics, Inc.
BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Reports Third Quarter 2021 Financial Results
09 déc. 2021 07h00 HE
|
Entrada Therapeutics, Inc.
Successful completion of upsized $208.7 million Initial Public Offering BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company...
Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
18 nov. 2021 08h00 HE
|
Entrada Therapeutics, Inc.
BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular...
Entrada Therapeutics Announces Closing of Initial Public Offering
02 nov. 2021 16h26 HE
|
Entrada Therapeutics, Inc.
BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™)...